VistaGen Therapeutics Acquires WW Rights for Pherin’s PH94B nasal spray for the Treatment of Social Anxiety Disorder

 VistaGen Therapeutics Acquires WW Rights for Pherin’s PH94B nasal spray for the Treatment of Social Anxiety Disorder

VistaGen Therapeutics Acquires WW Rights for Pherin’s PH94B nasal spray for the Treatment of Social Anxiety Disorder

Shots:

  • Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista
  • VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in H1’19) as a PRN treatment for SAD, in addition to an option to acquire Pherin’s CNS neuropsychiatry-focused product currently under P-II
  • The main focus of this agreement is to continue clinical trials for PH94B, showing its tolerance with no AEs & making an advancement in novel treatments for the patients affected with SAD. PH94B patents has been granted in the US, EU, Japan, China, Korea and other countries

Click here to read full press release/ article | Ref: VistaGen Therapeutics | Image: VistaGen

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post